Adjuvant therapy in the treatment of non-small-cell lung cancer.
Randomized trials to date have not consistently demonstrated a benefit in overall survival with the use of adjuvant chemotherapy, radiotherapy, or combined modality chemoradiation in patients with resected non-small-cell lung cancer. Subset analyses suggest a reduction in local relapse with adjuvant radiotherapy for patients with completely resected N2 disease. Improvements in patient selection and treatment plans are urgently needed.